Top

Published in:

01-10-2013 | Research Article

DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma

Authors: Yu-Zheng Xue, Tie-Long Wu, Yan-Min Wu, Ying-Yue Sheng, Zhe-Qiang Wei, Yu-Feng Lu, Li-Hua Yu, Jian-Ping Li, Zhao-Shen Li

Published in: Tumor Biology | Issue 5/2013

Abstract

Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies in humans, and its prognosis is generally poor even after surgery. Many advances have been made to understand the pathogenesis of PDA; however, the molecular mechanisms that lead to pancreatic carcinogenesis are still not clearly understood. The aims of this study were to investigate the relationship between DLC-1 methylation status and clinicopathological characteristics of PDA patients and evaluate the role of DLC-1 methylation status in PDA. The expression of DLC-1 mRNA in PDA tissues was analyzed by real-time PCR. The methylation status of DLC-1 was analyzed by methylation-specific polymerase chain reaction (MSP). Furthermore, we determined the prognostic importance of DLC-1 methylation status in PDA patients. Our results showed that the expression level of DLC-1 mRNA in PDA tissues was lower than that in non-cancerous tissues. The rate of DLC-1 promoter methylation was significantly higher in PDA tissues than in adjacent non-cancerous tissues (p < 0.001). Downregulation of DLC-1 was strongly correlated with promoter methylation (P = 0.003). The presence of DLC-1 methylation in PDA tissue samples was significantly correlated with clinical stage (P = 0.005), histological differentiation (P = 0.05), and lymph node metastasis (P = 0.006). Kaplan–Meier survival analysis showed that DLC-1 methylation status was inversely correlated with overall survival of the PDA patients. Further, Cox multivariate analysis indicated that DLC-1 methylation status was an independent prognostic factor for the overall survival rate of PDA patients. In conclusion, our data suggest that downregulation of DLC-1 may be explained by DNA methylation; DLC-1 may be a biomarker for PDA.

Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, et al. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol. 2012;3:326–34. doi:10.3978/j.issn.2078-6891.2012.029.PubMedCentralPubMed

Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6:597–612. doi:10.2217/bmm.12.69.PubMedCentralCrossRefPubMed

McCleary-Wheeler AL, Lomberk GA, Weiss FU, Schneider G, Fabbri M, Poshusta TL, et al. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 2013;328:212–21. doi:10.1016/j.canlet.2012.10.005.PubMedCentralCrossRefPubMed

Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol. 2012;18:4944–58. doi:10.3748/wjg.v18.i35.4944.PubMedCentralCrossRefPubMed

Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.PubMedCentralCrossRefPubMed

Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986;321:209–13.CrossRefPubMed

Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 1985;228:187–90. doi:10.1126/science.2579435.CrossRefPubMed

Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54. doi:10.1056/NEJMra023075.CrossRefPubMed

Peng D, Ren CP, Yi HM, Zhou L, Yang XY, Li H, et al. Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai). 2006;38:349–55. doi:10.1111/j.1745-7270.2006.00164.x.CrossRef

10.

Ullmannova V, Popescu NC. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol. 2006;29:1127–32.PubMed

11.

Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res. 2006;12:1412–9. doi:10.1158/1078-0432.CCR-05-1906.CrossRefPubMed

12.

Song YF, Xu R, Zhang XH, Chen BB, Chen Q, Chen YM, et al. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol. 2006;59:947–51. doi:10.1136/jcp.2005.031377.PubMedCentralCrossRefPubMed

13.

Feng X, Li C, Liu W, Chen H, Zhou W, Wang L, et al. DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells. Int J Oncol. 2013;42:1973–84. doi:10.3892/ijo.2013.1885.PubMed

14.

Liu H, Shi H, Hao Y, Zhao G, Yang X, Wang Y, et al. Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation. Mol Biol Rep. 2012;39:10665–70. doi:10.1007/s11033-012-1956-6.CrossRefPubMed

15.

Chen WT, Yang CH, Wu CC, Huang YC, Chai CY. Aberrant deleted in liver cancer-1 expression is associated with tumor metastasis and poor prognosis in urothelial carcinoma. APMIS. 2013. doi:10.1111/apm.12060.

16.

Peng H, Long F, Wu Z, Chu Y, Li J, Kuai R, Zhang J, Kang Z, Zhang X, Guan M. Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression. Biomed Res Int. 2013; 2013: 181384. doi:10.1155/2013/181384.

17.

Guan CN, Zhang PW, Lou HQ, Liao XH, Chen BY. DLC-1 expression levels in breast cancer assessed by qRT- PCR are negatively associated with malignancy. Asian Pac J Cancer Prev. 2012;13:1231–3.CrossRefPubMed

18.

Liu JB, Zhang YX, Zhou SH, Shi MX, Cai J, Liu Y, et al. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol. 2011;17:4718–24. doi:10.3748/wjg.v17.i42.4718.PubMedCentralCrossRefPubMed

19.

Feng M, Huang B, Du Z, Xu X, Chen Z. DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells. Mol Biol Rep. 2011;38(3):1915–20. doi:10.1007/s11033-010-0311-z.CrossRefPubMed

20.

Zhang T, Zheng J, Jiang N, Wang G, Shi Q, Liu C, et al. Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma. Cancer Lett. 2009;283:59–67. doi:10.1016/j.canlet.2009.03.025.CrossRefPubMed

21.

Zhang T, Zheng J, Liu C, Lu Y. Expression of DLC-1 in clear cell renal cell carcinoma: prognostic significance for progression and metastasis. Urol Int. 2009;82:380–7. doi:10.1159/000218524.CrossRefPubMed

22.

Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, et al. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene. 2007;26:6332–40. doi:10.1038/sj.onc.1210461.CrossRefPubMed

23.

Sun D, Zhang Z, Van do N, Huang G, Ernberg I, Hu L. Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol. 2007;43:82–7.CrossRefPubMed

24.

Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912–9.PubMed

Title: DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma
Authors: Yu-Zheng Xue
Tie-Long Wu
Yan-Min Wu
Ying-Yue Sheng
Zhe-Qiang Wei
Yu-Feng Lu
Li-Hua Yu
Jian-Ping Li
Zhao-Shen Li
Publication date: 01-10-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0846-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects

P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects

Association between MTHFR 677C>T polymorphism and risk of gliomas: evidence from a meta-analysis

Polymorphisms of DNA repair genes XPD, XRCC1, and OGG1, and lung adenocarcinoma susceptibility in Chinese population

Cytogenetic characterization of an N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse papillary urothelial carcinoma

Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial–mesenchymal transition in lung cancer cells via the NF-κB signaling pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer